OmniAb (OABI) news
Recent news
Shares of OmniaB jump 19.5% on $370 mln drug discovery deal with Eli Lilly
Shares of OmniAb, Inc. (NASDAQ: OABI) rose 19.5% following the announcement of a $370 million drug discovery collaboration with Eli Lilly and Company. The partnership leverages OmniAb’s proprietary antibody discovery platform, which includes transgenic animals such as OmniRat, OmniChicken, and…
AInvest Wire · Aug 17, 2026ImportantShares OmniaB jump 36.3% premarket on $370 mln drug discovery deal with Eli Lilly
AInvest Wire · Aug 17, 2026Omniab sees cash & cash equivalents in range of $49M to $53M
OmniAb, Inc. (NASDAQ: OABI) reported its fourth-quarter and full-year 2025 financial results on March 4, 2026, indicating that as of December 31, 2025, the company held cash, cash equivalents, and short-term investments totaling $54.0 million. This figure aligns with the company’s 2026 financial…
AInvest Wire · Aug 17, 2026Omniab raises 2026 financial guidance
Omniab has raised its full-year 2026 financial guidance following stronger-than-expected performance in the first half of the year. The company now anticipates revenue of €1.2 billion , up from its previous forecast of €1.1 billion. This upward revision reflects robust demand for its core products…
AInvest Wire · Aug 17, 2026OmniAb - to receive upfront payment and up to $370 mln in milestone payments plus royalties
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.